Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mech... Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company’s product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia. 詳細を表示
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.008 | -14.2857142857 | 0.056 | 0.058 | 0.048 | 26790708 | 0.05312676 | DE |
| 4 | -0.011 | -18.6440677966 | 0.059 | 0.066 | 0.048 | 22274321 | 0.05727286 | DE |
| 12 | 0.018 | 60 | 0.03 | 0.088 | 0.028 | 49356928 | 0.05998451 | DE |
| 26 | -0.227 | -82.5454545455 | 0.275 | 0.47 | 0.028 | 25257879 | 0.08636081 | DE |
| 52 | -0.232 | -82.8571428571 | 0.28 | 0.47 | 0.028 | 13245784 | 0.10196245 | DE |
| 156 | -0.257 | -84.262295082 | 0.305 | 0.485 | 0.028 | 5921879 | 0.16226332 | DE |
| 260 | -0.627 | -92.8888888889 | 0.675 | 0.715 | 0.028 | 4194725 | 0.20298808 | DE |
vuletini
12分前
MannSinger
15分前
Latenightmike57
18分前
chicks0123
20分前
jollyjack
23分前
JRyan
24分前
price_and_volume
42分前
jollyjack
43分前
vuletini
48分前
doinit
50分前
THEBEASTMUGABI
54分前
BlueSky195
1時間前
WooptdooU
1時間前
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
すでにアカウントをお持ちですか? サインイン
アカウントをお持ちでないですか? 登録
登録することで、ADVFN の 利用規約 を読み、理解し、同意したこと、および私が個人投資家であることを確認します。